Update in Women's Health: Evidence Published in 2010
Authors: Janet P. Pregler, Carolyn J. Crandall
Journal: Annals of Internal Medicine (2011)

Updates5 July 2011Update in Women's Health: Evidence Published in 2010Janet P. Pregler, MD and Carolyn J. Crandall, MD, MSJanet P. Pregler, MDFrom Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.Search for more papers by this author and Carolyn J. Crandall, MD, MSFrom Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-1-201107050-00341 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in Women's Health reviews important findings published in 2010. In the past year, studies added evidence to well-publicized debates about the risk for atypical femur fracture in bisphosphonate users and the relative benefits and risks of calcium and vitamin D supplementation. Newly identified risks of menopause hormone therapy are included. The update also reviews evidence for the efficacy of risk-reducing surgery for BRCA1 and BRCA2 mutation carriers who are at high risk for breast and ovarian cancer and human papillomavirus (HPV) testing as a primary screening method for cervical intraepithelial neoplasia and cancer. Information regarding nonpharmacologic treatment of ...References1. Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404-15. [PMID: 18794560] LinkGoogle Scholar2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008, updated 2010. Google Scholar3. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates [Editorial]. N Engl J Med. 2010;362:1825-7. [PMID: 20335574] CrossrefMedlineGoogle Scholar4. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24:1095-102. [PMID: 19113931] CrossrefMedlineGoogle Scholar5. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363:2027-35. [PMID: 21083387] CrossrefMedlineGoogle Scholar6. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Pr; 2010. Google Scholar7. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364:248-54. [PMID: 21247315] CrossrefMedlineGoogle Scholar8. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691. [PMID: 20671013] CrossrefMedlineGoogle Scholar9. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027-36. [PMID: 18460663] CrossrefMedlineGoogle Scholar10. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65. [PMID: 15998891] CrossrefMedlineGoogle Scholar11. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-27. [PMID: 12927427] CrossrefMedlineGoogle Scholar12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397] CrossrefMedlineGoogle Scholar13. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol. 2008;112:1189-92. [PMID: 18978127] CrossrefMedlineGoogle Scholar14. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al; Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230-50. [PMID: 17367675] CrossrefMedlineGoogle Scholar15. FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data [news release]. Silver Spring, MD: U.S. Food and Drug Administration; 8 January 2003. Google Scholar16. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143:355-61. [PMID: 16144894] LinkGoogle Scholar17. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144:397-406. [PMID: 16549852] LinkGoogle Scholar18. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295:2374-84. [PMID: 16720823] CrossrefMedlineGoogle Scholar19. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. [PMID: 17392385] CrossrefMedlineGoogle Scholar20. Screening for cervical cancer: recommendations and rationale. Am Fam Physician. 2003;67:1759-66. [PMID: 12725455] MedlineGoogle Scholar21. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 109, December 2009. Cervical cytology screening (replaces Practice Bulletin 45, August 2003). Obstet Gynecol. 2009;114:1409-20. [PMID: 20134296] MedlineGoogle Scholar22. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27-41. [PMID: 19147867] CrossrefMedlineGoogle Scholar23. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-55. [PMID: 17904957] CrossrefMedlineGoogle Scholar24. Nichols MI. Ulisprisal [sic] acetate: a novel molecule and 5-day emergency contraceptive [Editorial]. Obstet Gynecol. 2010;116:1252-3. [PMID: 21099587] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.Article relevant to primary care general internistsFinancial Support: From the Executive Advisory Board of the Iris Cantor-UCLA Women's Health Center, The Michael Parr Fund for Women's Health Education and Research.Disclosures: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-0246.Corresponding Author: Janet P. Pregler, MD, Iris Cantor-UCLA Women's Health Center, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90095; e-mail, [email protected]ucla.edu.Current Author Addresses: Dr. Pregler: Iris Cantor-UCLA Women's Health Center, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90095.Dr. Crandall: Division of General Internal Medicine, University of California, Los Angeles, 911 Broxton Avenue, First Floor, Los Angeles, CA 90024.Author Contributions: Conception and design: J.P. Pregler, C.J. Crandall.Drafting of the article: J.P. Pregler, C.J. Crandall.Critical revision of the article for important intellectual content: J.P. Pregler, C.J. Crandall.Final approval of the article: J.P. Pregler, C.J. Crandall. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTools to optimize the functionality of a leukemia clinical trial team 5 July 2011Volume 155, Issue 1Page: 52-57KeywordsBreast cancerCalciumCell biologyEstrogensFemurHormonal therapyHormonesHuman papillomavirusVitamin D ePublished: 5 July 2011 Issue Published: 5 July 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...